MDMA (ecstacy/molly Pills)
£120.00 – £230.00
3,4-Methyl
Description
What is MDMA (ecstacy/molly Pills)
MDMA (ecstacy/molly Pills) commonly known as ecstasy (tablet form), and molly or mandy (crystal form), is a potent empathogen–entactogen with stimulant and minor psychedelic properties. Investigational indications include as an adjunct to psychotherapy in the treatment of post-traumatic stress disorder (PTSD) and social anxiety in autism spectrum disorder. The purported pharmacological effects that may be prosocial include altered sensations, increased energy, empathy, and pleasure. When taken by mouth, effects begin in 30 to 45 minutes and last three to six hours.
- MDMA’s effects may include feeling more energetic and alert and having an increased sense of well-being, warmth, and openness toward others. However, MDMA can also cause unpleasant and potentially dangerous negative health effects.
- Though MDMA is commonly consume as an illicit drug, researchers are studying its use in therapeutic settings as a potential treatment for severe post-traumatic stress disorder (PTSD).
Abstract of MDMA (ecstacy/molly Pills)
Post-traumatic stress disorder (PTSD) presents a major public health problem for which currently available treatments are modestly effective. We report the findings of a randomize, double-blind, placebo-control, multi-site phase 3 clinical trial (NCT03537014). To test the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for the treatment of patients with severe PTSD, including those with common comorbidities such as dissociation, depression, a history of alcohol and substance use disorders, and childhood trauma. After psychiatric medication washout, participants (n = 90) were randomize 1:1 to receive manualize therapy with MDMA or with placebo, combined with three preparatory and nine integrative therapy sessions. PTSD symptoms, measure with the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5, the primary endpoint), and functional impairment, measure with the Sheehan Disability Scale (SDS, the secondary endpoint) were asses at baseline and at 2 months after the last experimental session. Adverse events and suicidality were track throughout the study.
MDMA was found to induce significant and robust attenuation in CAPS-5 score compare with placebo (P < 0.0001, d = 0.91) and to significantly decrease the SDS total score (P = 0.0116, d = 0.43). The mean change in CAPS-5 scores in participants completing treatment was −24.4 (s.d. 11.6) in the MDMA group and −13.9 (s.d. 11.5) in the placebo group. MDMA did not induce adverse events of abuse potential, suicidality or QT prolongation. These data indicate that, compare with manualize therapy with inactive placebo, MDMA-assisted therapy is highly efficacious in individuals with severe PTSD, and treatment is safe and well-tolerate, even in those with comorbidities. We conclude that MDMA-assisted therapy represents a potential breakthrough treatment that merits expedite clinical evaluation.
Main Continue…
PTSD is a common and debilitating condition with immeasurable social and economic costs that affects the lives of hundreds of millions of people annually. There are a number of environmental and biological risk factors that contribute to the development and maintenance of PTSD. Poor PTSD treatment outcomes are associate with several comorbid conditions that include childhood trauma, alcohol and substance use disorders, depression, suicidal ideation and dissociation.
It is therefore imperative to identify a therapeutic that is beneficial in those individuals with the comorbidities that typically confer treatment resistance.
Although, The selective serotonin reuptake inhibitors (SSRIs) sertraline and paroxetine are Food and Drug Administration (FDA)-approved first-line therapeutics for the treatment of PTSD. However, an estimated 40–60% of patients do not respond to these compounds. Likewise, although evidence-base trauma-focus psychotherapies such as prolong exposure and. Cognitive behavioral therapy are consider to be the gold standard treatments for PTSD, many participants fail to respond or continue to have significant symptoms, and dropout rates are high. Novel cost-effective therapeutics are therefore desperately need.
Main
In addition, the substitute amphetamine 3,4-methylenedioxymethamphetamine (MDMA) induces serotonin release by binding primarily to presynaptic serotonin transporters. MDMA has shown to enhance fear memory extinction, modulate fear memory reconsolidation (possibly through an oxytocin-dependent mechanism). And bolster social behavior in animal models. Pool analysis of six phase 2 trials of MDMA-assisted therapy for PTSD have now shown promising safety and efficacy findings.
However here, we assess the efficacy and safety of MDMA-assist therapy in individuals with severe PTSD. Participants were given three doses of MDMA or placebo in a control clinical environment and in the presence of a train therapy team. Primary and secondary outcome measures (CAPS-5 and SDS, respectively) were assess by a centralized pool of blind, independent diagnostic assessors. MDMA-assist therapy for PTSD was grant to FDA Breakthrough Therapy designation. And the protocol and statistical analysis plan (SAP) were develop in conjunction with the FDA.
Additional information
| variations | 10pills 170mg, 10pills 21Omg, 10pills 220mg, 10pills 250mg, 10pills 260mg, 10pills 280mg, 10pills 300mg, 10pills 330mg |
|---|
1 review for MDMA (ecstacy/molly Pills)
Related products
-
- PSYCHEDELIC
2C-B Pills
- £90.00 – £899.00
- Select options This product has multiple variants. The options may be chosen on the product page
vanesia lexi –
I have dealt with this company a few years now and I can honestly say with 100% confidence, ericpillsshop has never let me down, always given me great advice as to the intricacies of my prescription and item order details. It is a truly great company and I really appreciate our customer/supplier relationship…it’s something special!